Jun Teishima

Dr. Jun Teishima


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Sekino YoheiSekino Yohei
Sekino Yohei
XHXiangrui Han
Xiangrui Han
TKTakafumi Kawaguchi
Takafumi Kawaguchi
TBTakashi Babasaki
Takashi Babasaki
KGKeisuke Goto
Keisuke Goto
AMAkio Matsubara
Akio Matsubara
Recent studies have reported that TUBB3 overexpression is involved in docetaxel (DTX) resistance in prostate cancer (PCa). The aim of this study was to clarify the role of TUBB3 in DTX and cabazitaxel (CBZ) resistance, and cross-resistance between DTX and CBZ in PCa. We analyzed the effect of TUBB3 knockdown on DTX and CBZ resistance and examined the interaction between TUBB3 and PTEN. We also investigated the role of phosphoinositide 3-kinases (PI3K) inhibitor (LY294002) in DTX and CBZ resistance. TUBB3 expression was upregulated in DTX-resistant and CBZ-resistant cells. TUBB3 knockdown re-sensitized DTX-resistant cells to DTX and CBZ-resistant cells to CBZ. Additionally, TUBB3 knockdown re-sensitized DTX-resistant cell lines to CBZ, indicating that TUBB3 mediates cross-resistance between DTX and CBZ. Knockdown of TUBB3 enhanced PTEN expression, and PTEN knockout enhanced TUBB3 expression. LY294002 suppressed TUBB3 expression in DTX-resistant and CBZ-resistant cell lines. LY294002 re-sensitized DTX-resistant cell lines to DTX and CBZ-resistant cell lines to CBZ. These results suggest that TUBB3 is involved in DTX resistance and CBZ resistance. A combination of LY294002/DTX and that of LY294002/CBZ could be potential strategies for PCa treatment.

9 February 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Sekino YoheiSekino Yohei
Sekino Yohei
WYWataru Yasui
Wataru Yasui
YKYuki Koike
Yuki Koike
YSYoshinori Shigematsu
Yoshinori Shigematsu
NSNaoya Sakamoto
Naoya Sakamoto
WYWataru Yasui
Wataru Yasui
Kinesin family member C1 (KIFC1) is a minus end-directed motor protein that plays an essential role in centrosome clustering. Previously, we reported that KIFC1 is involved in cancer progression in prostate cancer (PCa). We designed this study to assess the involvement of KIFC1 in docetaxel (DTX) resistance in PCa and examined the effect of KIFC1 on DTX resistance. We also analyzed the possible role of a KIFC1 inhibitor (CW069) in PCa. We used DTX-resistant PCa cell lines in DU145 and C4-2 cells to analyze the effect of KIFC1 on DTX resistance in PCa. Western blotting showed that KIFC1 expression was higher in the DTX-resistant cell lines than in the parental cell lines. Downregulation of KIFC1 re-sensitized the DTX-resistant cell lines to DTX treatment. CW069 treatment suppressed cell viability in both parental and DTX-resistant cell lines. DTX alone had little effect on cell viability in the DTX-resistant cells. However, the combination of DTX and CW069 significantly reduced cell viability in the DTX-resistant cells, indicating that CW069 re-sensitized the DTX-resistant cell lines to DTX treatment. These results suggest that a combination of CW069 and DTX could be a potential strategy to overcome DTX resistance.

8 April 2015 in The Prostate
Verified
Journal Article
Closed access
PDF file
HNHirotaka Nagamatsu
Hirotaka Nagamatsu
JTJun Teishima
Jun Teishima
KGKeisuke Goto
Keisuke Goto
HSHiroyuki Shikuma
Hiroyuki Shikuma
HKHiroyuki Kitano
Hiroyuki Kitano
AMAkio Matsubara
Akio Matsubara

9 May 2018 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
JTJun Teishima
Jun Teishima
YTYukihiro Takayama
Yukihiro Takayama
SIShogo Iwaguro
Shogo Iwaguro
THTetsutaro Hayashi
Tetsutaro Hayashi
SIShogo Inoue
Shogo Inoue
AMAkio Matsubara
Akio Matsubara

1 November 2017 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
JTJun Teishima
Jun Teishima
KKKohei Kobatake
Kohei Kobatake
SSShunsuke Shinmei
Shunsuke Shinmei
SIShogo Inoue
Shogo Inoue
THTetsutaro Hayashi
Tetsutaro Hayashi
AMAkio Matsubara
Akio Matsubara

4 February 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
JTJun Teishima
Jun Teishima
THTetsutaro Hayashi
Tetsutaro Hayashi
HNHirotaka Nagamatsu
Hirotaka Nagamatsu
KSKoichi Shoji
Koichi Shoji
HSHiroyuki Shikuma
Hiroyuki Shikuma
AMAkio Matsubara
Akio Matsubara
Fibroblast growth factors (FGFs) and FGF receptors (FGFRs) play an important role in the maintenance of tissue homeostasis and the development and differentiation of prostate tissue through epithelial-stromal interactions. Aberrations of this signaling are linked to the development and progression of prostate cancer (PCa). The FGF family includes two subfamilies, paracrine FGFs and endocrine FGFs. Paracrine FGFs directly bind the extracellular domain of FGFRs and act as a growth factor through the activation of tyrosine kinase signaling. Endocrine FGFs have a low affinity of heparin/heparan sulfate and are easy to circulate in serum. Their biological function is exerted as both a growth factor binding FGFRs with co-receptors and as an endocrine molecule. Many studies have demonstrated the significance of these FGFs and FGFRs in the development and progression of PCa. Herein, we discuss the current knowledge regarding the role of FGFs and FGFRs—including paracrine FGFs, endocrine FGFs, and FGFRs—in the development and progression of PCa, focusing on the representative molecules in each subfamily.